ProQR Therapeutics (PRQR) Competitors $1.14 0.00 (0.00%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.18 +0.04 (+3.07%) As of 04/17/2025 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRQR vs. GHRS, ALMS, QURE, BCYC, KURA, URGN, MGTX, IMTX, ARVN, and SIONShould you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include GH Research (GHRS), Alumis (ALMS), uniQure (QURE), Bicycle Therapeutics (BCYC), Kura Oncology (KURA), UroGen Pharma (URGN), MeiraGTx (MGTX), Immatics (IMTX), Arvinas (ARVN), and Sionna Therapeutics (SION). These companies are all part of the "pharmaceutical products" industry. ProQR Therapeutics vs. GH Research Alumis uniQure Bicycle Therapeutics Kura Oncology UroGen Pharma MeiraGTx Immatics Arvinas Sionna Therapeutics GH Research (NASDAQ:GHRS) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, community ranking, media sentiment, valuation and risk. Which has more risk and volatility, GHRS or PRQR? GH Research has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Does the MarketBeat Community prefer GHRS or PRQR? ProQR Therapeutics received 306 more outperform votes than GH Research when rated by MarketBeat users. However, 76.92% of users gave GH Research an outperform vote while only 61.99% of users gave ProQR Therapeutics an outperform vote. CompanyUnderperformOutperformGH ResearchOutperform Votes3076.92% Underperform Votes923.08% ProQR TherapeuticsOutperform Votes33661.99% Underperform Votes20638.01% Do analysts rate GHRS or PRQR? GH Research presently has a consensus price target of $30.86, indicating a potential upside of 239.09%. ProQR Therapeutics has a consensus price target of $9.50, indicating a potential upside of 733.33%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than GH Research.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GH Research 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Which has higher valuation and earnings, GHRS or PRQR? ProQR Therapeutics has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGH ResearchN/AN/A-$35.59M-$0.75-12.13ProQR Therapeutics$18.91M6.34-$30.43M-$0.34-3.35 Is GHRS or PRQR more profitable? GH Research has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -134.31%. GH Research's return on equity of -20.29% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets GH ResearchN/A -20.29% -19.49% ProQR Therapeutics -134.31%-71.58%-19.70% Do insiders and institutionals have more ownership in GHRS or PRQR? 56.9% of GH Research shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 41.6% of GH Research shares are held by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor GHRS or PRQR? In the previous week, ProQR Therapeutics had 9 more articles in the media than GH Research. MarketBeat recorded 9 mentions for ProQR Therapeutics and 0 mentions for GH Research. ProQR Therapeutics' average media sentiment score of 0.82 beat GH Research's score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment GH Research Neutral ProQR Therapeutics Positive SummaryProQR Therapeutics beats GH Research on 10 of the 18 factors compared between the two stocks. Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRQR vs. The Competition Export to ExcelMetricProQR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$119.94M$6.44B$5.30B$7.35BDividend YieldN/A3.20%5.45%4.30%P/E Ratio-3.566.8921.8617.81Price / Sales6.34230.51380.6697.70Price / CashN/A65.6738.2634.64Price / Book2.075.936.453.98Net Income-$30.43M$142.99M$3.22B$247.81M1 Month Performance-30.06%-13.56%-9.76%-7.94%1 Year Performance-42.71%-8.89%11.49%1.52% ProQR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRQRProQR Therapeutics2.3804 of 5 stars$1.14flat$9.50+733.3%-38.7%$119.94M$18.91M-3.56180Short Interest ↓News CoverageGHRSGH Research2.4136 of 5 stars$9.32-7.6%$30.86+231.1%-18.7%$484.90MN/A-11.8010High Trading VolumeALMSAlumis2.4957 of 5 stars$10.07+0.2%$26.00+158.2%N/A$475.53MN/A0.00N/AHigh Trading VolumeQUREuniQure2.0986 of 5 stars$8.76-2.2%$38.80+342.9%+176.0%$473.72M$27.12M-1.77500Short Interest ↑News CoverageGap UpBCYCBicycle Therapeutics1.9507 of 5 stars$6.75-2.0%$29.14+331.7%-69.8%$467.11M$35.28M-2.05240News CoverageGap DownKURAKura Oncology4.1775 of 5 stars$5.76-2.2%$25.50+342.7%-66.6%$465.15M$53.88M-2.44130Positive NewsURGNUroGen Pharma4.283 of 5 stars$9.96-2.8%$38.20+283.5%-32.2%$459.10M$90.40M-3.16200Analyst ForecastNews CoverageMGTXMeiraGTx4.3514 of 5 stars$5.75+1.2%$24.50+326.1%+8.0%$453.42M$33.28M-4.75300Gap DownHigh Trading VolumeIMTXImmatics2.4928 of 5 stars$3.68+5.1%$16.67+352.9%-58.5%$439.23M$155.84M-5.58260Short Interest ↓Positive NewsGap UpHigh Trading VolumeARVNArvinas3.4642 of 5 stars$6.37-2.9%$35.50+457.3%-74.9%$438.08M$263.40M-2.30420Analyst ForecastShort Interest ↓High Trading VolumeSIONSionna TherapeuticsN/A$9.73-2.4%$38.50+295.7%N/A$429.33MN/A0.0035Gap Down Related Companies and Tools Related Companies GH Research Competitors Alumis Competitors uniQure Competitors Bicycle Therapeutics Competitors Kura Oncology Competitors UroGen Pharma Competitors MeiraGTx Competitors Immatics Competitors Arvinas Competitors Sionna Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRQR) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRQR Stock Free PRQR Stock Alerts